Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling

Lee,Harry; Saini,Nipun; Parris,Amanda B.; Zhao,Ming; Yang,Xiaohe

doi:10.3892/ijo.2017.4073

Ganetespib induces G2/M cell cycle arrest and apoptosis in gastric cancer cells through targeting of receptor tyrosine kinase signaling

Authors:
- Harry Lee
- Nipun Saini
- Amanda B. Parris
- Ming Zhao
- Xiaohe Yang
View Affiliations

Affiliations: Julius L. Chambers Biomedical/Biotechnology Research Institute, Department of Biological and Biomedical Sciences, North Carolina Central University, Kannapolis, NC 28081, USA
Published online on: July 13, 2017 https://doi.org/10.3892/ijo.2017.4073
Pages: 967-974

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heat shock protein 90 (HSP90) regulates several important cellular processes via its repertoire of ‘client proteins’. These client proteins have been found to play fundamental roles in signal transduction, cell proliferation, cell cycle progression and survival, as well as other features of malignant cells, such as invasion, tumor angiogenesis and metastasis. Thus, HSP90 is an emerging target for cancer therapy. To this end, we evaluated ganetespib (STA-9090), a novel and potent HSP90 inhibitor, for its activity in gastric cancer cell lines. Ganetespib significantly inhibited the proliferation of AGS and N87 human gastric cancer cell lines and potently induced G2/M cell cycle arrest and apoptosis. Upregulation of cleaved poly(ADP-ribose) polymerase (c-PARP), c-caspase-3, c-caspase-8 and c-caspase-9 and suppression of gastric cancer‑associated HSP90 client proteins, including ErbB2, Erk, Akt, mTOR, GSK3 and Src, were observed in ganetespib-treated cells. These findings demonstrate that the ganetespib-induced mechanism of cell growth inhibition involves the activation of death receptor and mitochondrial pathways and the inhibition of receptor tyrosine kinase signaling pathways. Our study implicates ganetespib as a potential strategy for gastric cancer treatment, which warrants further preclinical and clinical investigation.

View Figures

View References

1	Okamoto W, Okamoto I, Yoshida T, Okamoto K, Takezawa K, Hatashita E, Yamada Y, Kuwata K, Arao T, Yanagihara K, et al: Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther. 9:1188–1197. 2010. View Article : Google Scholar : PubMed/NCBI
2	American Cancer Society: Cancer Facts and Figures 2016. ACS; Atlanta, GA: 2016, http://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2016.html. Accessed date January 24, 2017.
3	Hartgrink HH, Jansen EP, van Grieken NC and van de Velde CJ: Gastric cancer. Lancet. 374:477–490. 2009. View Article : Google Scholar : PubMed/NCBI
4	Yasui W, Hata J, Yokozaki H, Nakatani H, Ochiai A, Ito H and Tahara E: Interaction between epidermal growth factor and its receptor in progression of human gastric carcinoma. Int J Cancer. 41:211–217. 1988. View Article : Google Scholar : PubMed/NCBI
5	Mi L, Ji X and Ji J: Prognostic biomarker in advanced gastric cancer. Transl Gastrointest Cancer. 5:16–29. 2016.
6	Aydin K, Okutur SK, Bozkurt M, Turkmen I, Namal E, Pilanci K, Ozturk A, Akcali Z, Dogusoy G and Demir OG: Effect of epidermal growth factor receptor status on the outcomes of patients with metastatic gastric cancer: A pilot study. Oncol Lett. 7:255–259. 2014.
7	Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
8	Moser C, Lang SA and Stoeltzing O: Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer. Anticancer Res. 29:2031–2042. 2009.PubMed/NCBI
9	Wang Y, Trepel JB, Neckers LM and Giaccone G: STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs. 11:1466–1476. 2010.PubMed/NCBI
10	Jhaveri K and Modi S: Ganetespib: Research and clinical development. Onco Targets Ther. 8:1849–1858. 2015.PubMed/NCBI
11	Liu H, Lu J, Hua Y, Zhang P, Liang Z, Ruan L, Lian C, Shi H, Chen K and Tu Z: Targeting heat-shock protein 90 with ganetespib for molecularly targeted therapy of gastric cancer. Cell Death Dis. 6:e15952015. View Article : Google Scholar : PubMed/NCBI
12	Mahata S, Maru S, Shukla S, Pandey A, Mugesh G, Das BC and Bharti AC: Anticancer property of Bryophyllum pinnata (Lam.) Oken. leaf on human cervical cancer cells. BMC Complement Altern Med. 12:152012. View Article : Google Scholar : PubMed/NCBI
13	Takayama S, Reed JC and Homma S: Heat-shock proteins as regulators of apoptosis. Oncogene. 22:9041–9047. 2003. View Article : Google Scholar : PubMed/NCBI
14	Jhaveri K, Ochiana SO, Dunphy MP, Gerecitano JF, Corben AD, Peter RI, Janjigian YY, Gomes-DaGama EM, Koren J III, Modi S, et al: Heat shock protein 90 inhibitors in the treatment of cancer: Current status and future directions. Expert Opin Investig Drugs. 23:611–628. 2014. View Article : Google Scholar : PubMed/NCBI
15	Den RB and Lu B: Heat shock protein 90 inhibition: Rationale and clinical potential. Ther Adv Med Oncol. 4:211–218. 2012. View Article : Google Scholar : PubMed/NCBI
16	Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y and Giaccone G: HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 33:4867–4876. 2014. View Article : Google Scholar :
17	Smith DL, Acquaviva J, Sequeira M, Jimenez JP, Zhang C, Sang J, Bates RC and Proia DA: The HSP90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer. Target Oncol. 10:235–245. 2015. View Article : Google Scholar :
18	Acquaviva J, Smith DL, Jimenez JP, Zhang C, Sequeira M, He S, Sang J, Bates RC and Proia DA: Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther. 13:353–363. 2014. View Article : Google Scholar : PubMed/NCBI
19	Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, et al: Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther. 12:509–519. 2013. View Article : Google Scholar : PubMed/NCBI
20	Burrows F, Zhang H and Kamal A: Hsp90 activation and cell cycle regulation. Cell Cycle. 3:1530–1536. 2004. View Article : Google Scholar : PubMed/NCBI
21	Srethapakdi M, Liu F, Tavorath R and Rosen N: Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest. Cancer Res. 60:3940–3946. 2000.PubMed/NCBI
22	Foijer F and te Riele H: Check, double check: The G2 barrier to cancer. Cell Cycle. 5:831–836. 2006. View Article : Google Scholar : PubMed/NCBI
23	DiPaola RS: To arrest or not to G(2)-M Cell-cycle arrest: commentary re: A.K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res. 8:3512–3519. 2002. Clin Cancer Res. 8:3311–3314. 2002.
24	Toyoshima H and Hunter T: p27 a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 78:67–74. 1994. View Article : Google Scholar : PubMed/NCBI
25	Foijer F, Delzenne-Goette E, Dekker M and Te Riele H: In vivo significance of the G2 restriction point. Cancer Res. 67:9244–9247. 2007. View Article : Google Scholar : PubMed/NCBI
26	Sawai H and Domae N: Discrimination between primary necrosis and apoptosis by necrostatin-1 in Annexin V-positive/propidium iodide-negative cells. Biochem Biophys Res Commun. 411:569–573. 2011. View Article : Google Scholar : PubMed/NCBI
27	Lang SA, Klein D, Moser C, Gaumann A, Glockzin G, Dahlke MH, Dietmaier W, Bolder U, Schlitt HJ, Geissler EK, et al: Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo. Mol Cancer Ther. 6:1123–1132. 2007. View Article : Google Scholar : PubMed/NCBI
28	Lu C, Liu D, Jin J, Deokar H, Zhang Y, Buolamwini JK, Yu X, Yan C and Chen X: Inhibition of gastric tumor growth by a novel Hsp90 inhibitor. Biochem Pharmacol. 85:1246–1256. 2013. View Article : Google Scholar : PubMed/NCBI
29	Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY and Bang YJ: Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci. 102:1388–1395. 2011. View Article : Google Scholar : PubMed/NCBI
30	Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, et al: Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 18:4973–4985. 2012. View Article : Google Scholar : PubMed/NCBI
31	Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, et al: A multi-center phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res. 19:3068–3077. 2013. View Article : Google Scholar : PubMed/NCBI
32	Ramalingam S, Goss G, Rosell R, Schmid-Bindert G, Zaric B, Andric Z, Bondarenko I, Komov D, Ceric T, Khuri F, et al: A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1). Ann Oncol. 26:1741–1748. 2015. View Article : Google Scholar : PubMed/NCBI
33	Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, et al: A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer. 14:154–160. 2014. View Article : Google Scholar : PubMed/NCBI